Why the study?
Does elevated cardiac troponin I (≥ 0.1 μg/L) measured by three different assays predict death, MI, or urgent revascularization in patients with non-ST-elevation acute coronary syndromes?
Does elevated cardiac troponin I (≥ 0.1 μg/L) measured by three different assays predict death, MI, or urgent revascularization in patients with non-ST-elevation acute coronary syndromes?
Three independently developed cTnI assays demonstrated similar prognostic efficacy at a threshold of 0.1 μg/L for predicting adverse outcomes in non-ST-elevation acute coronary syndromes.
No takes yet. Share an insight, caveat, or question.
Elevated cTnI may aid short-term risk stratification in NSTE-ACS across assays; leaves open whether assay-specific thresholds improve outcomes in prospective studies.
Morrow et al. (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: